{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:23:01Z","timestamp":1790310181126,"version":"4.1.0"},"reference-count":315,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"Introduction<\/jats:title>The role of public health has evolved from addressing infectious diseases to encompass non-communicable diseases. Individuals with genetic disorders and rare diseases constitute a particularly vulnerable population, requiring tailored public health policies, practical implementation strategies, and a long-term vision to ensure sustainable support. Given the prolonged duration and significant costs often associated with these conditions, comprehensive, patient-centered, and cost-effective approaches are essential to safeguard their physical and mental well-being.<\/jats:p><\/jats:sec>Aims<\/jats:title>To summarize definitions and concepts related to health, public health, rare diseases, and to highlight the role of integrating public health interventions into routine care in improving patient outcomes. Hemophilia was selected as an exemplary rare disease due to its significant lifetime treatment costs and the recent approval and pricing of its gene therapy as the world\u2019s most expensive drug, highlighting the critical importance of public health policies in ensuring equitable access to care and treatment.<\/jats:p><\/jats:sec>Methods<\/jats:title>A narrative literature review was conducted between July 2023 and December 2024, searching PubMed, Google Scholar, and Google for various topics related to rare diseases, public health, and hemophilia.<\/jats:p><\/jats:sec>Results<\/jats:title>Public health can play an important role in improving the health outcomes of people with rare diseases by implementing conceptual and applied models to accomplish a set of objectives. Over the past two decades, legislative and regulatory support in high income countries (HICs) has facilitated the development and approval of diagnostics and treatments for several rare diseases leading to important advancements. In contrast, many low- and middle-income countries (LMICs) face obstacles in enacting legislation, developing regulations, and implementing policies to support rare disease diagnosis and treatment. More investment and innovation in drug discovery and market access pathways are still needed in both LMICs and HICs. Ensuring the translation of public health policies into regulatory measures, and in turn implementing, and regularly evaluating these measures to assess their effectiveness is crucial. In the case of hemophilia, public health can play a pivotal role.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Enhancing public health surveillance, policies, and interventions in hemophilia and other rare diseases can bridge data gaps, support access to equitable treatment, promote evidence-based care, and improve outcomes across the socioeconomic spectrum.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1450625","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:41:42Z","timestamp":1742456502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of public health in rare diseases: hemophilia as an example"],"prefix":"10.3389","volume":"13","author":[{"given":"Amr A.","family":"El-Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike M.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Bolous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"ref1","first-page":"113","article-title":"Rare disease registries","volume-title":"Registries for evaluating patient outcomes: a user\u2019s guide","author":"Dale","year":"2014"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s43441-022-00409-w","article-title":"Global regulatory and public health initiatives to advance pediatric drug development for rare diseases","volume":"56","author":"Epps","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4415\/ANN_19_03_10","article-title":"Value based healthcare for rare diseases: efficiency, efficacy, equity","volume":"55","author":"Fantini","year":"2019","journal-title":"Ann Ist Super Sanita"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.rare.2023.100004","article-title":"The role of medical students in advocacy for rare diseases \u2013 experience from a Low- and Middle-Income Country (LMIC)","volume":"1","author":"Qamar","year":"2023","journal-title":"Rare"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.55085\/aph.2022.637","article-title":"Return on investment from the prevention of orphan diseases in Kuwait","volume":"1","author":"Abuhadida","year":"2022","journal-title":"Ann Public Heal"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5582\/irdr.2023.01005","article-title":"Carrier screening programs for rare diseases in developed countries and the case of Turkey: a systematic review","volume":"12","author":"Fidan","year":"2023","journal-title":"Intractable Rare Dis Res."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jfma.2013.06.017","article-title":"Cost-effectiveness analysis of carrier and prenatal genetic testing for X-linked hemophilia","volume":"114","author":"Tsai","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"ref8","article-title":"The burden of rare diseases: an economic evaluation","author":"Andreu","year":""},{"key":"ref9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.7322\/jhgd.46349","article-title":"The evolving role of public health in the delivery of health care","volume":"22","author":"Atrash","year":"2012","journal-title":"J Hum Growth Dev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0020731418782653","article-title":"The definition of health: towards new perspectives","volume":"48","author":"Leonardi","year":"2018","journal-title":"Int J Heal Serv"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"d4163","DOI":"10.1136\/bmj.d4163","article-title":"How should we define health?","volume":"343","author":"Huber","year":"2011","journal-title":"BMJ"},{"key":"ref12","article-title":"Bleeding disorders","volume-title":"StatPearls","author":"Doherty","year":"2023"},{"key":"ref13","unstructured":"2024"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s41669-024-00540-4","article-title":"Economic burden of haemophilia from a societal perspective: a scoping review","volume":"9","author":"El-Sayed","year":"2025","journal-title":"PharmacoEconomics Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/hae.14926","article-title":"The psychosocial impact of haemophilia from patients\u2019 and caregivers\u2019 point of view: the results of an Italian survey","volume":"30","author":"Fornari","year":"2024","journal-title":"Haemophilia"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JBM.S291536","article-title":"Optimizing haemophilia care in resource-limited countries: current challenges and future prospects","volume":"14","author":"Ndoumba-Mintya","year":"2023","journal-title":"J Blood Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e62817","DOI":"10.7759\/cureus.62817","article-title":"Improving hemophilia care in low- and middle-income countries: addressing challenges and enhancing quality of life","volume":"16","author":"Perolla","year":"2024","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biom14070854","article-title":"Recent advances in gene therapy for hemophilia: projecting the perspectives","volume":"14","author":"Chernyi","year":"2024","journal-title":"Biomol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2147\/JBM.S371438","article-title":"Gene therapy and hemophilia: where do we go from here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J Blood Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/hae.14984","article-title":"Current and emerging gene therapies for haemophilia A and B","volume":"30","author":"Kaczmarek","year":"2024","journal-title":"Haemophilia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/hae.13009","article-title":"Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study","volume":"22","author":"Lane","year":"2016","journal-title":"Haemophilia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1016\/S2352-3026(21)00132-0","article-title":"The case for equitable haemophilia care","volume":"8","author":"Srivastava","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s11846-022-00588-8","article-title":"Literature reviews as independent studies: guidelines for academic practice","volume":"16","author":"Kraus","year":"2022","journal-title":"Rev Manag Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/publications11010002","article-title":"The science of literature reviews: searching, identifying, selecting, and synthesising","volume":"11","author":"Chigbu","year":"2023","journal-title":"Publica"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1891\/9780826131867.0005","article-title":"Key principles for searching the literature","volume-title":"Comprehensive systematic review for advanced nursing practice","author":"Saimbert","year":"2017"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1891\/9780826121844.0011","article-title":"Basic literature search strategies","volume-title":"Introduction to quality and safety education for nurses: core competencies","author":"Thomson","year":"2014"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2105\/AJPH.36.11.1315","article-title":"Constitution of the World Health Organization","volume":"36","year":"1946","journal-title":"Am J Public Health Nations Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/milmed\/usy213","article-title":"Toward a contemporary definition of health","volume":"183","author":"Bradley","year":"2018","journal-title":"Mil Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.puhe.2019.03.023","article-title":"Defining health and health inequalities","volume":"172","author":"McCartney","year":"2019","journal-title":"Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"101129","DOI":"10.1016\/j.dhjo.2021.101129","article-title":"It\u2019s time to reconsider how we define health: perspective from disability and chronic condition","volume":"14","author":"Krahn","year":"2021","journal-title":"Disabil Health J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3325\/cmj.2017.58.431","article-title":"Concepts and definitions of health and health-related values in the knowledge landscapes of the digital society","volume":"58","author":"Svalastog","year":"2017","journal-title":"Croat Med J"},{"key":"ref34","unstructured":"2023"},{"key":"ref35","unstructured":"2023"},{"key":"ref36","unstructured":"2023"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.puhe.2005.01.010","article-title":"Public health in practice: the three domains of public health","volume":"119","author":"Griffiths","year":"2005","journal-title":"Public Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1186\/s12889-018-5677-1","article-title":"The effects of public health policies on health inequalities in high-income countries: an umbrella review","volume":"18","author":"Thomson","year":"2018","journal-title":"BMC Public Health"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.puhe.2007.05.013","article-title":"The three domains of public health: an internationally relevant basis for public health education?","volume":"122","author":"Thorpe","year":"2008","journal-title":"Public Health"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.32481\/djph.2018.03.004","article-title":"Public health, population health, and planning: ideas to improve communities","volume":"4","author":"Baba","year":"2018","journal-title":"Delaware J Public Heal"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1891\/9780826148346.0001","article-title":"Overview of community, public, and population health","volume-title":"Population health for nurses: improving community outcomes","author":"Mager","year":"2019"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2105\/AJPH.2016.303097","article-title":"On the distinction\u2014or lack of distinction\u2014between population health and public health","volume":"106","author":"Roux","year":"2016","journal-title":"Am J Public Health"},{"key":"ref43","unstructured":"2004"},{"key":"ref44","unstructured":"2020"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.amepre.2012.01.021","article-title":"The structure and organization of local and state public health agencies in the U.S.: a systematic review","volume":"42","author":"Hyde","year":"2012","journal-title":"Am J Prev Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fpubh.2014.00088","article-title":"Public health education in south asia: a basis for structuring a master degree course","volume":"2","author":"Karkee","year":"2014","journal-title":"Front Public Health"},{"key":"ref47","unstructured":"2024"},{"key":"ref48","first-page":"1","volume-title":"Social determinants of health: the solid facts","author":"Wilkinson","year":"2003"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S0140-6736(08)61690-6","article-title":"Closing the gap in a generation: health equity through action on the social determinants of health","volume":"372","author":"Marmot","year":"2008","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/00333549141291S206","article-title":"The social determinants of health: it\u2019s time to consider the causes of the causes","volume":"129","author":"Braveman","year":"2014","journal-title":"Public Health Rep"},{"key":"ref51","unstructured":""},{"key":"ref52","unstructured":"2022"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jamacardio.2019.3805","article-title":"A theoretical framework for clinical implementation of social determinants of health","volume":"4","author":"Hammond","year":"2019","journal-title":"JAMA Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fpubh.2019.00011","article-title":"Social determinants of health and related inequalities: confusion and implications","volume":"7","author":"Islam","year":"2019","journal-title":"Front Public Health"},{"key":"ref55","first-page":"1","volume-title":"Social determinants of health: the Canadian facts","author":"Raphael","year":"2020"},{"key":"ref56","unstructured":"Determinants of health\n \n 2017"},{"key":"ref57","volume-title":"Regional Office for the Eastern Mediterranean. Assessment of essential public health functions in countries of the Eastern Mediterranean Region: assessment tool","year":"2017"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.0887-378X.2004.00303.x","article-title":"Social determinants and their unequal distribution: clarifying policy understandings","volume":"82","author":"Graham","year":"2004","journal-title":"Milbank Q"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1097\/PHH.0000000000001297","article-title":"Addressing health equity and social determinants of health through healthy people 2030","volume":"27","author":"G\u00f3mez","year":"2021","journal-title":"J Public Heal Manag Pract"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.puhe.2012.05.014","article-title":"Fair society, healthy lives","volume":"126","author":"Marmot","year":"2012","journal-title":"Public Health"},{"key":"ref61","volume-title":"A conceptual framework for action on the Social Determinants of Health Discussion Paper 2 (Policy and Practice)","author":"Solar","year":"2010"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1466424006070466","article-title":"A health map for the local human habitat","volume":"126","author":"Barton","year":"2006","journal-title":"J Roy Soc Promot Health"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drudis.2012.08.009","article-title":"Orphan drugs: the regulatory environment","volume":"18","author":"Franco","year":"2013","journal-title":"Drug Discov Today"},{"key":"ref64","first-page":"1","volume-title":"Rare diseases and orphan products: accelerating research and development","author":"Field","year":"2010"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5582\/irdr.2018.01085","article-title":"A compilation of national plans, policies and government actions for rare diseases in 23 countries","volume":"7","author":"Khosla","year":"2018","journal-title":"Intractable Rare Dis Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1517\/21678707.2013.769876","article-title":"Orphan drug designation\u2013Europe, the USA and Japan","volume":"1","author":"O\u2019Connor","year":"2013","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Heal J Int Soc Pharmacoeconomics Outcomes Res."},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.bbadis.2015.02.008","article-title":"Rare disease policies to improve care for patients in Europe","volume":"1852","author":"Rodwell","year":"2015","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref69","unstructured":"2016"},{"key":"ref70","unstructured":"Birkelund\n CH\n \n \n \n 2019"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fpubh.2022.1028545","article-title":"Rare disease emerging as a global public health priority","volume":"10","author":"Chung","year":"2022","journal-title":"Front Public Health"},{"key":"ref73","first-page":"100434","article-title":"Advancing rare disease policy in Latin America: a call to action","volume":"18","author":"Wainstock","year":"2023","journal-title":"Lancet Reg Heal Am"},{"key":"ref74","first-page":"1","article-title":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products","volume":"15","year":"2000","journal-title":"OJ L 18"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"E05","DOI":"10.5888\/pcd13.150491","article-title":"Public health and rare diseases: oxymoron no more","volume":"13","author":"Valdez","year":"2016","journal-title":"Prev Chronic Dis"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/978-3-319-67144-4_30","article-title":"The European Union policy in the field of rare diseases","volume-title":"Rare diseases epidemiology: update and overview","author":"Moliner","year":"2017"},{"key":"ref77","unstructured":"2019"},{"key":"ref78","unstructured":"2021"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1046\/j.1365-2516.2002.00643.x","article-title":"Orphan drugs: legal aspects, current situation","volume":"8","author":"Lavandeira","year":"2002","journal-title":"Haemophilia"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5582\/irdr.2018.01065","article-title":"National information system for rare diseases with an approach to data architecture: a systematic review","volume":"7","author":"Derayeh","year":"2018","journal-title":"Intractable Rare Dis Res"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"15174","DOI":"10.3390\/ijerph192215174","article-title":"Health policies for rare disease patients: a scoping review","volume":"19","author":"Lopes-J\u00fanior","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"30","DOI":"10.22270\/ijdra.v4i3.187","article-title":"Regulations of orphan drugs in USA, EU and India-a comparative study","volume":"4","author":"Budhwar","year":"2016","journal-title":"Int J Drug Regul Aff"},{"key":"ref83","unstructured":"2023"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e1002191","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the orphan drug act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med"},{"key":"ref85","first-page":"541","article-title":"The orphan drug act: how the FDA unlawfully usurped market exclusivity","volume":"11","author":"Kim","year":"2013","journal-title":"Nw J Tech Intell Prop"},{"key":"ref86","unstructured":"2023"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08998280.2022.2048613","article-title":"Rarely mentioned: how we arrived at the quantitative definition of a rare disease","volume":"35","author":"Partin","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/shm\/hkx098","article-title":"Orphans in the market: the history of orphan drug policy","volume":"32","author":"Mikami","year":"2019","journal-title":"Soc Hist Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1517\/21678707.2013.832201","article-title":"Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research","volume":"1","author":"Song","year":"2013","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5582\/irdr.2012.v1.1.3","article-title":"Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives","volume":"1","author":"Song","year":"2012","journal-title":"Intractable Rare Dis Res"},{"key":"ref91","unstructured":""},{"key":"ref92","unstructured":"2023"},{"key":"ref93","unstructured":""},{"key":"ref94","unstructured":"2015"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13023-019-1032-6","article-title":"The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011-2015","volume":"14","author":"Lim","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40246-019-0215-5","article-title":"Genomics of rare genetic diseases\u2014experiences from India","volume":"13","author":"Bajaj","year":"2019","journal-title":"Hum Genomics"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"e0001498","DOI":"10.1371\/journal.pgph.0001498","article-title":"Assessment of the availability of repurposed orphan drugs in India","volume":"3","author":"Rajueni","year":"2023","journal-title":"PLOS Glob Public Heal"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.4103\/ijo.IJO_302_22","article-title":"Ophthalmic registries for rare eye diseases","volume":"70","author":"Sharma","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3348\/kjr.2020.1171","article-title":"Rare neurovascular diseases in Korea: classification and related genetic variants","volume":"22","author":"Song","year":"2021","journal-title":"Korean J Radiol"},{"key":"ref100","unstructured":"Ertok\n \u00d6\n \n \n Akbil\n \u015e\n \n \n Cebeci\n Z\n \n \n \n 2023"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13023-020-1314-z","article-title":"A civil society view of rare disease public policy in six Latin American countries","volume":"15","author":"Mayrides","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref102","unstructured":"2021"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.32383\/appdr\/90995","article-title":"Bridging East with West of Europe \u2013 A comparison of orphan drug policies in Poland, Russia and the Netherlands","volume":"75","author":"Czech","year":"2019","journal-title":"Acta Pol Pharm Drug Res"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries","volume":"7","author":"Czech","year":"2019","journal-title":"Front Public Health"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"e0204206","DOI":"10.1371\/journal.pone.0204206","article-title":"Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan\u2019s National Health Insurance Research Database","volume":"13","author":"Hsu","year":"2018","journal-title":"PLoS One"},{"key":"ref106","unstructured":"Schouten\n A.\n \n \n \n 2020"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5582\/irdr.2022.01034","article-title":"The definition of rare disease in China and its prospects","volume":"11","author":"Lu","year":"2022","journal-title":"Intractable Rare Dis Res"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1111\/hae.14529","article-title":"Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States","volume":"28","author":"Miller","year":"2022","journal-title":"Haemophilia"},{"key":"ref109","first-page":"645","article-title":"The child in context of the family, community, and society","volume-title":"McDonald and Avery\u2019s dentistry for the child and adolescent","author":"Edelstein","year":"2016"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2015.08.015","article-title":"Current and future burden of chronic nonmalignant liver disease","volume":"13","author":"Udompap","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12889-019-6820-3","article-title":"Calculating incidence rates and prevalence proportions: not as simple as it seems","volume":"19","author":"Spronk","year":"2019","journal-title":"BMC Public Health"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.130675","article-title":"Estimating disease prevalence and incidence using administrative data: some assembly required","volume":"40","author":"Ward","year":"2013","journal-title":"J Rheumatol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00038-014-0552-z","article-title":"Calculating disability-adjusted life years to quantify burden of disease","volume":"59","author":"Devleesschauwer","year":"2014","journal-title":"Int J Public Health"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.hcl.2019.07.015","article-title":"A systematic review of orthopedic global outreach efforts based on WHO-CHOICE thresholds","volume":"35","author":"Nolte","year":"2019","journal-title":"Hand Clin"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","article-title":"Cost-of-illness studies in rare diseases: a scoping review","volume":"16","author":"Garc\u00eda-P\u00e9rez","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"914338","DOI":"10.3389\/fphar.2022.914338","article-title":"Valuing the \u201cburden\u201d and impact of rare diseases: a scoping review","volume":"13","author":"Delaye","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/ijerph18031101","article-title":"Reflections on the importance of cost of illness analysis in rare diseases: a proposal","volume":"18","author":"Armeni","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13023-022-02283-z","article-title":"Assessing the value of orphan drugs using conventional cost-effectiveness analysis: is it fit for purpose?","volume":"17","author":"Postma","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-022-02337-2","article-title":"Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients","volume":"17","author":"Zanello","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"ref121","volume-title":"Population statistics","year":"2006"},{"key":"ref122","unstructured":"2023"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"ref125","article-title":"Hemophilia","volume-title":"StatPearls","author":"Mehta","year":"2024"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.rpth.2023.100047","article-title":"Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status","volume":"7","author":"Rejt\u0151","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman","year":"2022","journal-title":"Blood Adv"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"Malec","year":"2023","journal-title":"Haemophilia"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/jcm11030801","article-title":"Current choices and management of treatment in persons with severe hemophilia A without inhibitors: a mini-Delphi consensus","volume":"11","author":"Coppola","year":"2022","journal-title":"J Clin Med"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10826-024-02790-6","article-title":"Living with a rare disease: psychosocial impacts for parents and family members \u2013 a systematic review","volume":"33","author":"Atkins","year":"2024","journal-title":"J Child Fam Stud"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/children9070933","article-title":"Psychosocial considerations for the child with rare disease: a review with recommendations and calls to action","volume":"9","author":"Belzer","year":"2022","journal-title":"Children"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/13603116.2021.1888323","article-title":"The psychosocial impact of rare diseases among children and adolescents attending mainstream schools in Western Australia","volume":"27","author":"Adama","year":"2023","journal-title":"Int J Incl Educ"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13023-023-02837-9","article-title":"Living with a rare disease - experiences and needs in pediatric patients and their parents","volume":"18","author":"Witt","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"e033353","DOI":"10.1136\/bmjopen-2019-033353","article-title":"Perceived burden in dealing with different rare diseases: a qualitative focus group study","volume":"9","author":"Uhlenbusch","year":"2019","journal-title":"BMJ Open"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13023-022-02595-0","article-title":"The psychosocial situation of families caring for children with rare diseases during the COVID-19 pandemic: results of a cross-sectional online survey","volume":"17","author":"Rihm","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.18553\/jmcp.2024.30.7-b.s1","article-title":"Impact of mental health in persons living with rare disease: findings from the AMCP Market Insights Program","volume":"30","author":"Richardson","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/rdodj.2022.04","article-title":"Psychological support at diagnosis of a rare disease","volume":"1","author":"Kenny","year":"2022","journal-title":"A Rev Lit Rare Dis Res Partners"},{"key":"ref138","unstructured":"Palagyi\n A\n \n \n Sengupta\n A\n \n \n Moorthy\n M\n \n \n Malik\n C\n \n \n Barratt\n J\n \n \n Devuyst\n O\n \n \n \n 2024"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: a systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Policy"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"100711","DOI":"10.1016\/j.lanwpc.2023.100711","article-title":"Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study","volume":"34","author":"Chung","year":"2023","journal-title":"Lancet Reg Heal Pacific"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.4081\/ejtm.2021.9610","article-title":"Evaluation of orphan diseases global burden","volume":"31","author":"Makarova","year":"2021","journal-title":"Eur J Transl Myol"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","article-title":"The national economic burden of rare disease in the United States in 2019","volume":"17","author":"Yang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s13023-022-02524-1","article-title":"Rare disease curative care expenditure-financing scheme-health provider\u2013beneficiary group analysis: an empirical study in Sichuan Province, China","volume":"17","author":"Li","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","article-title":"Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J Med Econ"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0660-y","article-title":"The cost of severe haemophilia in Europe: the CHESS study","volume":"12","author":"O\u2019Hara","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","article-title":"Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1080\/13696998.2021.1965388","article-title":"Cost of hemophilia A in Turkey: an economic disease burden analysis","volume":"24","author":"Malhan","year":"2021","journal-title":"J Med Econ"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hae.12324","article-title":"Out-of-pocket and catastrophic expenditure on treatment of haemophilia by Indian families","volume":"20","author":"Dharmarajan","year":"2014","journal-title":"Haemophilia"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1750-1172-9-37","article-title":"A population-based registry as a source of health indicators for rare diseases: the ten-year experience of the Veneto Region\u2019s rare diseases registry","volume":"9","author":"Mazzucato","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref152","first-page":"65","article-title":"Existing surveillance data sources and systems","volume-title":"A nationwide framework for surveillance of cardiovascular and chronic lung diseases","year":"2011"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6064\/2012\/875253","article-title":"The past, present, and future of public health surveillance","volume":"2012","author":"Choi","year":"2012","journal-title":"Scientifica (Cairo)"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-publhealth-031816-044348","article-title":"Public health surveillance systems: recent advances in their use and evaluation","volume":"38","author":"Groseclose","year":"2017","journal-title":"Annu Rev Public Health"},{"key":"ref156","first-page":"997","article-title":"Public health surveillance: a tool for targeting and monitoring interventions","volume-title":"Disease Control Priorities in Developing Countries","author":"Nsubuga","year":"2006"},{"key":"ref157","unstructured":"2023"},{"key":"ref158","unstructured":"2018"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oso\/9780190933692.003.0005","article-title":"Using technologies for data collection and management","volume-title":"The CDC field epidemiology manual, Part I","author":"Hamilton","year":"2019"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.NAJ.0000794280.73744.fe","article-title":"Cross-sectional studies","volume":"121","author":"Capili","year":"2021","journal-title":"Am J Nurs"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"s144","DOI":"10.1179\/102453312X13336169156537","article-title":"Public health surveillance and data collection: general principles and impact on hemophilia care","volume":"17","author":"Soucie","year":"2012","journal-title":"Hematology"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6905a1","article-title":"Evaluation of CDC\u2019s hemophilia surveillance program - universal data collection (1998-2011) and community counts (2011-2019), United States","volume":"69","author":"Schieve","year":"2020","journal-title":"MMWR Surveill Summ"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/hae.13734","article-title":"Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources","volume":"25","author":"Okolo","year":"2019","journal-title":"Haemophilia"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.amepre.2014.07.008","article-title":"Meeting the emerging public health needs of persons with blood disorders","volume":"47","author":"Parker","year":"2014","journal-title":"Am J Prev Med"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ajh.23704","article-title":"National surveillance for hemophilia inhibitors in the United States: summary report of an expert meeting","volume":"89","author":"Soucie","year":"2014","journal-title":"Am J Hematol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/hae.12302","article-title":"A study of prospective surveillance for inhibitors among persons with haemophilia in the United States","volume":"20","author":"Soucie","year":"2014","journal-title":"Haemophilia"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1111\/hae.12448","article-title":"Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry","volume":"20","author":"Fischer","year":"2014","journal-title":"Haemophilia"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The world federation of hemophilia annual global survey 1999-2018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"ref169","unstructured":"2023"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"102264","DOI":"10.1016\/j.rpth.2023.102264","article-title":"The world federation of hemophilia world bleeding disorders registry: insights from the first 10,000 patients","volume":"7","author":"Coffin","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0049-3848(10)70150-X","article-title":"EUHASS: the European haemophilia safety surveillance system","volume":"127","author":"Makris","year":"2011","journal-title":"Thromb Res"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"E137","DOI":"10.1002\/ajh.25076","article-title":"Community counts: Evolution of a national surveillance system for bleeding disorders","volume":"93","author":"Manco-Johnson","year":"2018","journal-title":"Am J Hematol"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17474086.2017.1272410","article-title":"The current state of adverse event reporting in hemophilia","volume":"10","author":"van Vulpen","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/hae.14993","article-title":"The importance and evolution of bleeding disorder registries","volume":"30","author":"Tran","year":"2024","journal-title":"Haemophilia"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/hae.12406","article-title":"Enhancing haemophilia care through registries","volume":"20","author":"Dolan","year":"2014","journal-title":"Haemophilia"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"11968","DOI":"10.3390\/ijerph182211968","article-title":"The quality evaluation of rare disease registries\u2014an assessment of the essential features of a disease registry","volume":"18","author":"Ali","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-022-02290-0","article-title":"Nationwide comprehensive epidemiological study of rare diseases in Japan using a health insurance claims database","volume":"17","author":"Ninomiya","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref178","unstructured":"2021"},{"key":"ref179","unstructured":"2015"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5455\/medarh.2020.74.47-53","article-title":"Evidence-based public health policy models development and evaluation using big data analytics and web technologies","volume":"74","author":"Moutselos","year":"2020","journal-title":"Med Arch (Sarajevo, Bosnia Herzegovina)"},{"key":"ref181","unstructured":"2015"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-319-67144-4_4","article-title":"Improved diagnosis and care for rare diseases through implementation of precision public health framework","volume-title":"Rare diseases epidemiology: update and overview","author":"Baynam","year":"2017"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/cts.13270","article-title":"The economics of moonshots: value in rare disease drug development","volume":"15","author":"Yates","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref184","unstructured":"2023"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/gim.2016.166","article-title":"The need for a next-generation public health response to rare diseases","volume":"19","author":"Valdez","year":"2017","journal-title":"Genet Med"},{"key":"ref186","article-title":"Regulatory framework for the treatment of orphan diseases","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"Shah","year":"2006"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.3.1","article-title":"The current status of orphan drug development in Europe and the US","volume":"3","author":"Hall","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","article-title":"Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries","volume":"10","author":"Gammie","year":"2015","journal-title":"PLoS One"},{"key":"ref189","first-page":"45","article-title":"Research and development on intractable & rare diseases in Japan: Contribution of the National Institute of Public Health to research program management","volume":"68","author":"Takemura","year":"2019","journal-title":"J Natl Inst Public Heal"},{"key":"ref190","unstructured":"2023"},{"key":"ref191","unstructured":"1983"},{"key":"ref192","unstructured":"2001"},{"key":"ref193","first-page":"67","article-title":"Opinion of the European Economic and Social Committee on Ensuring strong European solidarity for rare disease patients","volume":"10","year":"2023","journal-title":"OJ C 75"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"13319","DOI":"10.3390\/ijerph192013319","article-title":"A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China","volume":"19","author":"Mu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2217\/cer-2022-0120","article-title":"The next generation of rare disease drug policy: ensuring both innovation and affordability","volume":"11","author":"Pearson","year":"2022","journal-title":"J Comp Eff Res"},{"key":"ref196","unstructured":"2023"},{"key":"ref197","unstructured":"2022"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref199","volume-title":"Political Declaration of the High-Level Plenary Meeting on Universal Health Coverage: resolution 74\/2\/adopted by the General Assembly on 10 October 2019","year":"2019"},{"key":"ref200","volume-title":"Addressing the challenges of persons living with a rare disease and their families: resolution 76\/132\/adopted by the General Assembly on 16 December 2021","year":"2021"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4415\/ANN_22_02_01","article-title":"The long journey of people with rare diseases: from darkness to the UN Resolution 2021","volume":"58","author":"Taruscio","year":"2022","journal-title":"Ann Ist Super Sanita"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/d41573-022-00019-z","article-title":"Research on rare diseases: ten years of progress and challenges at IRDiRC","volume":"21","author":"Monaco","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"Future of rare diseases research 2017-2027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20517\/rdodj.2021.02","article-title":"IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward strategic actions","volume":"1","author":"Hivert","year":"2022","journal-title":"Rare Dis Orphan Drugs J"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","article-title":"Economic modeling considerations for rare diseases","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Heal J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: no easy answers","volume":"21","author":"Ollendorf","year":"2018","journal-title":"Value Heal"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2021.631527","article-title":"How to value orphan drugs? A review of european value assessment frameworks","volume":"12","author":"Blonda","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"861067","DOI":"10.3389\/fpubh.2022.861067","article-title":"Influencing factors of health technology assessment to orphan drugs: empirical evidence in England, Scotland, Canada, and Australia","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fphar.2024.1498386","article-title":"Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries","volume":"15","author":"Jakubowski","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref210","volume-title":"Innovative payment models for high-cost innovative medicines. Report of the Expert Panel on effective ways of investing in Health (EXPH)","year":"2018"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","article-title":"Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis","volume":"23","author":"Chan","year":"2020","journal-title":"Value Health"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"114","DOI":"10.33393\/grhta.2021.2278","article-title":"Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?","volume":"8","author":"Jommi","year":"2021","journal-title":"Glob Reg Heal Technol Assess"},{"key":"ref213","volume-title":"Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward","author":"Wenzl","year":"2019"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fphar.2023.1074512","article-title":"Orphan drugs\u2019 clinical uncertainty and prices: addressing allocative and technical inefficiencies in orphan drug reimbursement","volume":"14","author":"Eichler","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1017\/S0266462323000053","article-title":"Novel approach to decision making for orphan drugs","volume":"39","author":"Decker","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000464100","article-title":"Reimbursed price of orphan drugs: current strategies and potential improvements","volume":"20","author":"Mincarone","year":"2017","journal-title":"Public Health Genomics"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/13696998.2022.2077550","article-title":"Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis","volume":"25","author":"Rubin","year":"2022","journal-title":"J Med Econ"},{"key":"ref218","unstructured":"2021"},{"key":"ref219","unstructured":"2012"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12687-020-00488-y","article-title":"Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide","volume":"12","author":"Cornel","year":"2021","journal-title":"J Community Genet"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijns7010015","article-title":"Neonatal screening in europe revisited: an ISNS perspective on the current state and developments since 2010","volume":"7","author":"Loeber","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000360602","article-title":"European recommendations for primary prevention of congenital anomalies","volume":"17","author":"Taruscio","year":"2014","journal-title":"Public Health Genomics"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jdv.17165","article-title":"Epidemiology of rare diseases is important","volume":"35","author":"Bruckner-Tuderman","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"963601","DOI":"10.3389\/fped.2022.963601","article-title":"A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010-2020","volume":"10","author":"Chang","year":"2022","journal-title":"Front Pediatr"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"561873","DOI":"10.3389\/fpubh.2021.561873","article-title":"Convergence of precision medicine and public health into precision public health: toward a big data perspective","volume":"9","author":"Velmovitsky","year":"2021","journal-title":"Front Public Health"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fpubh.2019.00042","article-title":"Optimizing precision medicine for public health","volume":"7","author":"Bilkey","year":"2019","journal-title":"Front Public Health"},{"key":"ref227","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fpubh.2018.00068","article-title":"Big data\u2019s role in precision public health","volume":"6","author":"Dolley","year":"2018","journal-title":"Front Public Health"},{"key":"ref228","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1057\/s41271-022-00367-5","article-title":"Precision public health: is it all about the data?","volume":"43","author":"Naumova","year":"2022","journal-title":"J Public Health Policy England"},{"key":"ref229","doi-asserted-by":"publisher","first-page":"2300163","DOI":"10.1002\/gch2.202300163","article-title":"Biomedical big data technologies, applications, and challenges for precision medicine: a review","volume":"8","author":"Yang","year":"2024","journal-title":"Glob Challenges"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gim.2021.08.015","article-title":"Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases","volume":"24","author":"Incerti","year":"2022","journal-title":"Genet Med"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"920390","DOI":"10.3389\/fgene.2022.920390","article-title":"Incomplete penetrance and variable expressivity: from clinical studies to population cohorts","volume":"13","author":"Kingdom","year":"2022","journal-title":"Front Genet"},{"key":"ref232","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/genes11030239","article-title":"Genetic modifiers and rare mendelian disease","volume":"11","author":"Rahit","year":"2020","journal-title":"Genes (Basel)"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fgene.2023.1258083","article-title":"Artificial intelligence and database for NGS-based diagnosis in rare disease","volume":"14","author":"Choon","year":"2024","journal-title":"Front Genet"},{"key":"ref234","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.ejmg.2024.104951","article-title":"Addressing diagnostic gaps and priorities of the global rare diseases community: recommendations from the IRDiRC diagnostics scientific committee","volume":"70","author":"Adams","year":"2024","journal-title":"Eur J Med Genet"},{"key":"ref235","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13023-024-03352-1","article-title":"Artificial intelligence empowering rare diseases: a bibliometric perspective over the last two decades","volume":"19","author":"Ou","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13023-024-03361-0","article-title":"Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases","volume":"19","author":"van Karnebeek","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases8040042","article-title":"Precision medicine in rare diseases","volume":"8","author":"Villal\u00f3n-Garc\u00eda","year":"2020","journal-title":"Dis (Basel, Switzerland)"},{"key":"ref238","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrd.2017.226","article-title":"Drug development in the era of precision medicine","volume":"17","author":"Dugger","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"ref239","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"ref240","unstructured":"2021"},{"key":"ref241","unstructured":"2019"},{"key":"ref242","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/d41573-024-00020-8","article-title":"The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases","volume":"23","author":"Brooks","year":"2024","journal-title":"Nat Rev Drug Discov England"},{"key":"ref243","unstructured":"2021"},{"key":"ref244","unstructured":"2024"},{"key":"ref245","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-023-02650-4","article-title":"Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force","volume":"18","author":"Nabbout","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref246","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/JBM.S325031","article-title":"Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders","volume":"12","author":"Valentino","year":"2021","journal-title":"J Blood Med"},{"key":"ref247","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/17474086.2023.2171981","article-title":"Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia","volume":"16","author":"Tran","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"ref248","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17474086.2023.2183836","article-title":"Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science","volume":"16","author":"Byams","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"ref249","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13023-021-02061-3","article-title":"The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems","volume":"16","author":"Tisdale","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref250","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/pubmed\/fdt048","article-title":"A Toolkit to assess health needs for congenital disorders in low- and middle-income countries: an instrument for public health action","volume":"36","author":"Nacul","year":"2014","journal-title":"J Public Health (Bangkok)"},{"key":"ref251","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12687-018-0390-4","article-title":"Congenital disorders: epidemiological methods for answering calls for action","volume":"9","author":"Modell","year":"2018","journal-title":"J Community Genet"},{"key":"ref252","unstructured":"2023"},{"key":"ref253","first-page":"63","article-title":"Genetic determinants of disease and genetics in public health","volume-title":"Maxcy-Rosenau-last public health and preventive medicine","author":"Lorey","year":"2017"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/B978-0-12-801282-6.00003-6","article-title":"Concepts of health and disease","volume-title":"Integrative approaches for health: biomedical research, ayurveda, and yoga","author":"Patwardhan","year":"2015"},{"key":"ref255","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1750-1172-8-109","article-title":"Sustainable rare diseases business and drug access: no time for misconceptions","volume":"8","author":"Rollet","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"ref256","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-6-49","article-title":"The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases","volume":"6","author":"Miyamoto","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref257","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.3390\/ijerph20064732","article-title":"Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges","volume":"20","author":"Adachi","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref258","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","article-title":"Recommendations from the European working group for value assessment and funding processes in rare diseases (ORPH-VAL)","volume":"12","author":"Annemans","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref259","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/medethics-2021-107691","article-title":"Should rare diseases get special treatment?","volume":"48","author":"Magalhaes","year":"2022","journal-title":"J Med Ethics"},{"key":"ref260","doi-asserted-by":"publisher","DOI":"10.32388\/LGHFL8","article-title":"the plight of rare diseases in southern Africa: health and social services policy recommendations","author":"David","year":"2023","journal-title":"Qeios"},{"key":"ref261","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41588-019-0552-2","article-title":"A call for global action for rare diseases in Africa","volume":"52","author":"Baynam","year":"2020","journal-title":"Nat Genet"},{"key":"ref262","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.hlpt.2019.11.008","article-title":"Regulatory issues for orphan medicines: a review","volume":"9","author":"Bouwman","year":"2020","journal-title":"Heal Policy Technol"},{"key":"ref263","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13023-021-01923-0","article-title":"Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group","volume":"16","author":"Gahl","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref264","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-017-0618-0","article-title":"Review of 11 national policies for rare diseases in the context of key patient needs","volume":"12","author":"Dharssi","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref265","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4415\/ANN_17_02_16","article-title":"Sustainable public health systems for rare diseases","volume":"53","author":"Ferrelli","year":"2017","journal-title":"Ann Ist Super Sanita"},{"key":"ref266","doi-asserted-by":"publisher","first-page":"100537","DOI":"10.1016\/j.hlpt.2021.100537","article-title":"Evaluation of rare diseases policy performance of oecd countries using mcdm methods","volume":"10","author":"Ince","year":"2021","journal-title":"Heal Policy Technol"},{"key":"ref267","doi-asserted-by":"publisher","first-page":"1026064","DOI":"10.3389\/fphar.2022.1026064","article-title":"Editorial: Prevention, diagnosis and treatment of rare disorders","volume":"13","author":"Cox","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref268","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fmed.2023.1180550","article-title":"Policy analysis in the field of rare diseases in China: a combined study of content analysis and Bibliometrics analysis","volume":"10","author":"Li","year":"2023","journal-title":"Front Med"},{"key":"ref269","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.glmedi.2023.100032","article-title":"Burden of rare diseases in Africa: recommendations for improving access to medications and healthcare","volume":"2","author":"Edu","year":"2024","journal-title":"J Med Surgery Public Heal"},{"key":"ref270","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s13023-022-02498-0","article-title":"Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases","volume":"17","author":"Kaywanga","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref271","unstructured":"2022"},{"key":"ref272","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tips.2019.02.008","article-title":"Care for rare: spotlight on rare diseases","volume":"40","author":"Mukherjee","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"ref273","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-022-02192-1","article-title":"Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise","volume":"17","author":"Verma","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref274","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-024-03030-2","article-title":"Coding undiagnosed rare disease patients in health information systems: recommendations from the RD-CODE project","volume":"19","author":"Angin","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref275","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4415\/ANN_19_03_15","article-title":"Patient empowerment of people living with rare diseases. Its contribution to sustainable and resilient healthcare systems","volume":"55","author":"De Santis","year":"2019","journal-title":"Ann Ist Super Sanita"},{"key":"ref276","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41927-022-00247-1","article-title":"Empowering rare disease patients through patient education: the new Beh\u00e7eTalk programme","volume":"6","author":"Marinello","year":"2022","journal-title":"BMC Rheumatol"},{"key":"ref277","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/S0140-6736(08)60875-2","article-title":"Empowerment of patients: lessons from the rare diseases community","volume":"371","author":"Aym\u00e9","year":"2008","journal-title":"Lancet"},{"key":"ref278","doi-asserted-by":"publisher","first-page":"FRD22","DOI":"10.2217\/frd-2022-0003","article-title":"The global role of patients, advocates and caregivers in rare diseases","volume":"2","author":"Nori","year":"2023","journal-title":"Futur Rare Dis"},{"key":"ref279","article-title":"Prevention strategies","volume-title":"StatPearls","author":"Kisling","year":"2023"},{"key":"ref280","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/hae.13008","article-title":"NHF-McMaster guideline on care models for haemophilia management","volume":"22","author":"Pai","year":"2016","journal-title":"Haemophilia"},{"key":"ref281","doi-asserted-by":"publisher","first-page":"e12488","DOI":"10.1002\/rth2.12488","article-title":"Patient-relevant health outcomes for hemophilia care: development of an international standard outcomes set","volume":"5","author":"van Balen","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"ref282","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3324\/haematol.2019.242735","article-title":"Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies","volume":"105","author":"Peyvandi","year":"2020","journal-title":"Haematologica"},{"key":"ref283","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.amepre.2014.07.007","article-title":"A public health approach to the prevention of inhibitors in hemophilia","volume":"47","author":"Soucie","year":"2014","journal-title":"Am J Prev Med"},{"key":"ref284","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/bmjinnov-2020-000425","article-title":"Patient access to gene therapy medicinal products: a comprehensive review","volume":"7","author":"Carvalho","year":"2021","journal-title":"BMJ Innov"},{"key":"ref285","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther"},{"key":"ref286","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13023-016-0458-3","article-title":"Rare disease landscape in Brazil: report of a successful experience in inborn errors of metabolism","volume":"11","author":"Giugliani","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref287","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s13023-024-03392-7","article-title":"Epidemiological characterization of rare diseases in Brazil: a retrospective study of the Brazilian Rare Diseases Network","volume":"19","author":"de Oliveira","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref288","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.4268.1","article-title":"The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US\/EU and in Latin America","volume":"4","author":"Arnold","year":"2015","journal-title":"F1000Research"},{"key":"ref289","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13023-023-02881-5","article-title":"Initiatives to promote access to medicines after publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases","volume":"18","author":"Cunico","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref290","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fpubh.2023.1127713","article-title":"Rarecare: a policy perspective on the burden of rare diseases on caregivers in Latin America","volume":"11","author":"Dias","year":"2023","journal-title":"Front Public Health"},{"key":"ref291","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-023-02667-9","article-title":"Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review","volume":"18","author":"Gittus","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref292","doi-asserted-by":"publisher","first-page":"e0170365","DOI":"10.1371\/journal.pone.0170365","article-title":"Clinical practice guidelines for rare diseases: the orphanet database","volume":"12","author":"Pavan","year":"2017","journal-title":"PLoS One"},{"key":"ref293","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref294","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/healthcare9030296","article-title":"Pricing and reimbursement pathways of new orphan drugs in South Korea: a longitudinal comparison","volume":"9","author":"Lee","year":"2021","journal-title":"Healthc (Basel, Switzerland)"},{"key":"ref295","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2471\/BLT.15.163519","article-title":"Negotiating prices of drugs for rare diseases","volume":"94","author":"Henrard","year":"2016","journal-title":"Bull World Health Organ"},{"key":"ref296","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-016-0780-7","article-title":"Social\/economic costs and health-related quality of life in patients with rare diseases in Europe","volume":"17","author":"L\u00f3pez-Bastida","year":"2016","journal-title":"Eur J Heal Econ"},{"key":"ref297","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/jpc.15507","article-title":"Rare diseases research and policy in Australia: on the journey to equitable care","volume":"57","author":"Bhattacharya","year":"2021","journal-title":"J Paediatr Child Health"},{"key":"ref298","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.csbj.2024.11.051","article-title":"CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: collaborative translation of scientific discoveries into advanced treatments for neurological rare genetic diseases and cancer","volume":"27","author":"Marolt Presen","year":"2025","journal-title":"Comput Struct Biotechnol J"},{"key":"ref299","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-981-99-4491-0_26","article-title":"Connecting each other in rare diseases: a call for cross-regional collaboration BT","volume-title":"Gaps and actions in health improvement from hong kong and beyond: all for health","author":"Sheng","year":"2023"},{"key":"ref300","doi-asserted-by":"publisher","first-page":"100783","DOI":"10.1016\/j.lanepe.2023.100783","article-title":"Rare diseases: still on the fringes of universal health coverage in Europe","volume":"37","author":"Tumien\u0117","year":"2024","journal-title":"Lancet Reg Heal Eur"},{"key":"ref301","doi-asserted-by":"publisher","first-page":"dmm050623","DOI":"10.1242\/dmm.050623","article-title":"Improving access to gene therapy for rare diseases","volume":"17","author":"Fox","year":"2024","journal-title":"Dis Model Mech"},{"key":"ref302","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41588-022-01027-w","article-title":"A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States","volume":"54","author":"Halley","year":"2022","journal-title":"Nat Genet"},{"key":"ref303","doi-asserted-by":"publisher","first-page":"800","DOI":"10.35808\/ersj\/2265","article-title":"Integrative medicine as a new treatment model and the future of health care systems in the world in the context of rare diseases","author":"Czerska","year":"2021","journal-title":"Eur Res Stud J"},{"key":"ref304","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biotech13010001","article-title":"Gene therapy for genetic syndromes: understanding the current state to guide future care","volume":"13","author":"Henderson","year":"2024","journal-title":"Biotech"},{"key":"ref305","doi-asserted-by":"publisher","first-page":"e56661","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep"},{"key":"ref306","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther"},{"key":"ref307","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17474086.2023.2184341","article-title":"New directions to develop therapies for people with hemophilia","volume":"16","author":"Gogia","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"ref308","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hae.15031","article-title":"Moving towards normalization of haemostasis and health equity: evolving treatment goals for haemophilia A","volume":"30","author":"Holme","year":"2024","journal-title":"Haemophilia"},{"key":"ref309","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/hae.14956","article-title":"Diagnosis and treatment challenges in lower resource countries: state-of-the-art","volume":"30","author":"Mahlangu","year":"2024","journal-title":"Haemophilia"},{"key":"ref310","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13023-023-02892-2","article-title":"Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis","volume":"18","author":"Yoon","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref311","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13023-023-02853-9","article-title":"Together4RD position statement on collaboration between European reference networks and industry","volume":"18","author":"Hedley","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref312","doi-asserted-by":"publisher","first-page":"1138996","DOI":"10.3389\/fphar.2023.1138996","article-title":"Long way to go: progress of orphan drug accessibility in China from 2017 to 2022","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref313","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/d41573-021-00045-3","article-title":"Orphan drug designation and development in Japan: 25 years of experience and assessment","volume":"20","author":"Sakushima","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref314","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13023-019-1261-8","article-title":"Rare diseases in Chile: challenges and recommendations in universal health coverage context","volume":"14","author":"Encina","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"ref315","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/irdr.2021.01027","article-title":"An update on China\u2019s national policies regarding rare diseases","volume":"10","author":"Ying","year":"2021","journal-title":"Intractable Rare Dis Res"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1450625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:44:20Z","timestamp":1742456660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1450625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":315,"alternative-id":["10.3389\/fpubh.2025.1450625"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1450625","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1450625"}}